for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Seelos Therapeutics Inc

SEEL.OQ

Latest Trade

1.96USD

Change

-0.04(-2.00%)

Volume

79,913

Today's Range

1.91

 - 

2.00

52 Week Range

0.57

 - 

6.60

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
2.00
Open
1.96
Volume
79,913
3M AVG Volume
52.89
Today's High
2.00
Today's Low
1.91
52 Week High
6.60
52 Week Low
0.57
Shares Out (MIL)
102.32
Market Cap (MIL)
204.63
Forward P/E
-3.65
Dividend (Yield %)
--

Next Event

Seelos Therapeutics Inc at Maxim Group and M-Vest Virtual Conference Series

Latest Developments

More

Seelos Therapeutics Announces Senior Management Appointments

Seelos Therapeutics Inc Announces Its Inclusion In First U.S. Listed Exchange Traded Fund (ETF) Focused On Psychedelics

Seelos Therapeutics Announces Pricing Of $60 Mln Public Offering Of Common Stock

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Seelos Therapeutics Inc

Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of products that address unmet needs in central nervous system (CNS) disorders and other rare disorders. The Company’s lead programs SLS-002 for the treatment of acute suicidal ideation and behavior (ASIB) in depressive disorder (MDD), and SLS-005 for the potential treatment of amyotrophic lateral sclerosis (ALS). SLS-005 for the potential treatment of Sanfilippo Syndromes, which is being explored. It is also developing several preclinical programs, including SLS-010, an oral histamine H3A receptor antagonist that shows promising activity in narcolepsy and related disorders, and SLS-012, an injectable therapy for post-operative pain management. The Company’s ongoing programs include SLS-004, SLS-006, SLS-007, and SLS-008.

Industry

Biotechnology & Drugs

Contact Info

300 PARK AVENUE, 2ND FLOOR

NEW YORK, NY

10022

United States

+1.646.2932100

https://seelostherapeutics.com/

Executive Leadership

Raj Mehra

Chairman of the Board, President, Chief Executive Officer

Michael Joseph Golembiewski

Chief Financial Officer

Anthony Marciano

Chief Communications Officer

Margaret Dalesandro

Director

Richard W. Pascoe

Director

Key Stats

1.83 mean rating - 6 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.0K

2019

0.0K

2020

0.0K

2021(E)

0.0K
EPS (USD)

2019

-2.520

2020

-0.430

2021(E)

-0.548
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
2.47
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.01
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-88.77
Return on Equity (TTM)
-78.54

Latest News

Latest News

BRIEF-Seelos Therapeutics Announces Initiation Of Preclinical Study Of SLS-007 In Parkinson's Disease

* SEELOS THERAPEUTICS ANNOUNCES INITIATION OF PRECLINICAL STUDY OF SLS-007 IN PARKINSON'S DISEASE

BRIEF-Seelos Announces Final Data From Phase I Pk/Pd Study Of Intranasal Racemic Ketamine

* SEELOS THERAPEUTICS ANNOUNCES FINAL DATA FROM PHASE I PK/PD STUDY OF INTRANASAL RACEMIC KETAMINE (SLS-002) AND CLINICAL DEVELOPMENT PLANS

BRIEF-Seelos Therapeutics Announces Initiation Of Preclinical Study Of SLS-004 In Parkinson's Disease

* SEELOS THERAPEUTICS ANNOUNCES INITIATION OF PRECLINICAL STUDY OF SLS-004 IN PARKINSON’S DISEASE Source text for Eikon: Further company coverage:

BRIEF-Seelos Therapeutics Receives Rare Pediatric Disease Designation For SLS-005 In Sanfilippo Syndrome

* SEELOS THERAPEUTICS RECEIVES RARE PEDIATRIC DISEASE DESIGNATION FOR SLS-005 (TREHALOSE) IN SANFILIPPO SYNDROME Source text for Eikon: Further company coverage:

BRIEF-Seelos Therapeutics Receives Notice Of Allowance For U.S. Patent For Trehalose

* SEELOS THERAPEUTICS RECEIVES NOTICE OF ALLOWANCE FOR AN ADDITIONAL US PATENT FOR TREHALOSE (SLS-005) Source text for Eikon: Further company coverage:

BRIEF-Seelos Therapeutics Receives Notice Of Delisting Or Failure To Satisfy Continued Listing Rule From Nasdaq

* SEELOS THERAPEUTICS INC - ON APR 14, GOT NOTICE OF DELISTING OR FAILURE TO SATISFY A CONTINUED LISTING RULE OR STANDARD FROM NASDAQ Source text: (https://bit.ly/3cphNu7) Further company coverage:

BRIEF-Seelos Therapeutics Announces Pricing Of $4.5 Mln Public Offering Of Common Stock

* SEELOS THERAPEUTICS ANNOUNCES PRICING OF $4.5 MILLION PUBLIC OFFERING OF COMMON STOCK

BRIEF-Seelos Therapeutics Announces Proposed Public Offering Of Common Stock

* SEELOS THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK Source text for Eikon: Further company coverage:

BRIEF-Seelos Therapeutics Announces European Medicines Agency Guidance To Design An Open-Label Study For Sls-005

* SEELOS THERAPEUTICS ANNOUNCES EUROPEAN MEDICINES AGENCY GUIDANCE TO DESIGN AN OPEN-LABEL PIVOTAL STUDY FOR SLS-005 IN SANFILIPPO SYNDROME

BRIEF-Seelos Therapeutics Receives Notice Of Allowance For Composition Of Matter Patent For SLS-007

* SEELOS THERAPEUTICS RECEIVES NOTICE OF ALLOWANCE FOR COMPOSITION OF MATTER PATENT FOR SLS-007 Source text for Eikon: Further company coverage:

BRIEF-Seelos Therapeutics Announces Additional Interim Data From Phase I Studies Of Intranasal Racemic Ketamine

* SEELOS THERAPEUTICS ANNOUNCES ADDITIONAL INTERIM DATA FROM PHASE I STUDIES OF INTRANASAL RACEMIC KETAMINE (SLS-002)

BRIEF-Seelos Therapeutics Announces Pricing Of $5 Mln Public Offering Of Common Stock

* SEELOS THERAPEUTICS ANNOUNCES PRICING OF $5 MILLION PUBLIC OFFERING OF COMMON STOCK

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up